Division of Interventional Radiology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
Division of Interventional Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
AJR Am J Roentgenol. 2021 Jun;216(6):1558-1565. doi: 10.2214/AJR.20.23156. Epub 2021 Apr 21.
The purpose of this study was to report national utilization trends and outcomes after percutaneous cholecystostomy, cholecystectomy, or no intervention among patients admitted to hospitals with acute cholecystitis. The Nationwide Inpatient Sample was queried from 2005 to 2014. Admissions were identified and stratified into treatment groups of percutaneous cholecystostomy, cholecystectomy, and no intervention on the basis of International Classification of Diseases, 9th revision, codes. Outcomes, including length of stay, inpatient mortality, and complications including hemorrhage and bile peritonitis, were identified. Multivariate analysis was performed to identify mortality risk by treatment type after adjustment for baseline comorbidities and risk of mortality. Among 2,550,013 patients (58.6% women, 41.4% men; mean age, 55.9 years) admitted for acute cholecystitis over the study duration, 73,841 (2.9%) patients underwent percutaneous cholecystostomy, 2,005,728 (78.7%) underwent cholecystectomy, and 459,585 (18.0%) did not undergo either procedure. Use of percutaneous cholecystostomy increased from 2985 procedures in 2005 to 12,650 in 2014. The percutaneous cholecystostomy cohort had a higher mean age (70.6 years) than the other two groups (cholecystectomy, 53.8 years; no intervention, 62.5 years), a higher mean comorbidity index (cholecystostomy, 3.74; cholecystectomy, 1.77; no intervention, 2.65), and a higher mean risk of mortality index (cholecystostomy, 2.88; cholecystectomy, 1.45; no intervention, 2.07) ( < .05). Unadjusted inpatient all-cause mortality was 10.1% in the percutaneous cholecystostomy, 0.8% in the cholecystectomy, and 5.2% in the no intervention cohorts. After adjustment for baseline mortality risk, percutaneous cholecystostomy (odds ratio, 0.78; 95% CI, 0.76-0.81) and cholecystectomy (odds ratio, 0.42; 95% CI, 0.41-0.43) were associated with reduced mortality compared with no intervention. Use of percutaneous cholecystostomy is increasing among patients admitted with acute cholecystitis. After adjustment for baseline comorbidities, percutaneous cholecystostomy is associated with improved odds of survival compared with no intervention.
本研究旨在报告在因急性胆囊炎住院的患者中,经皮胆囊造口术、胆囊切除术和无干预治疗的全国利用趋势和结局。从 2005 年至 2014 年,使用国家住院患者样本进行了查询。根据国际疾病分类第 9 版代码,将入院患者分为经皮胆囊造口术、胆囊切除术和无干预治疗组。确定了包括住院时间、住院死亡率和包括出血和胆汁性腹膜炎在内的并发症等结局。进行了多变量分析,以确定在调整基线合并症和死亡率风险后,按治疗类型划分的死亡率风险。在研究期间因急性胆囊炎入院的 255 万 013 名患者中(58.6%为女性,41.4%为男性;平均年龄 55.9 岁),73841 名(2.9%)患者接受了经皮胆囊造口术,2005728 名(78.7%)患者接受了胆囊切除术,459585 名(18.0%)患者未接受任何治疗。2005 年,经皮胆囊造口术的使用例数为 2985 例,到 2014 年增加到 12650 例。经皮胆囊造口术组的平均年龄(70.6 岁)高于其他两组(胆囊切除术组,53.8 岁;无干预组,62.5 岁),平均合并症指数(经皮胆囊造口术组,3.74;胆囊切除术组,1.77;无干预组,2.65)和平均死亡率风险指数(经皮胆囊造口术组,2.88;胆囊切除术组,1.45;无干预组,2.07)均较高(均<0.05)。经皮胆囊造口术组、胆囊切除术组和无干预组的未调整住院全因死亡率分别为 10.1%、0.8%和 5.2%。在调整了基线死亡率风险后,与无干预相比,经皮胆囊造口术(比值比,0.78;95%置信区间,0.76-0.81)和胆囊切除术(比值比,0.42;95%置信区间,0.41-0.43)与降低死亡率相关。在因急性胆囊炎住院的患者中,经皮胆囊造口术的使用率正在增加。在调整了基线合并症后,与无干预相比,经皮胆囊造口术与生存几率的提高相关。